retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 First 3 data, a Triumph of Science! Retatrutide: A Triple Agonist Shaping

10.1155/2018/4315413 Int J Endocrinol

While tirzepatide made history as the first dual GIP/GLP-1 receptor agonist to receive FDA approval, retatrutide pushes the pharmacological envelope further with triple receptor agonism that adds glucagon receptor activation

Thanks to this, it can be taken at any time, regardless of meals or time of day, making it easier for patients to adhere to the regimen

Starting Safely With Autoimmune Disease Most providers who are comfortable prescribing GLP-1s to patients with autoimmune conditions will recommend a slower-than-standard dose escalation

Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, et al

The glucagon receptor activation drives this effect by promoting hepatic fat oxidation, essentially telling the liver to burn its stored fat reserves